Pharmafile Logo

Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program

Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural member of ISPOR—The Professional Society for Health Economics and Outcomes Research’s Corporate Partnership Program. This strategic alliance with ISPOR reinforces Genesis Research Group’s commitment to advancing HEOR to inform healthcare decision-making and improve patient access to life-changing therapies.

ISPOR partner seal

As a member of ISPOR’s Corporate Partnership Program, Genesis Research Group will collaborate with ISPOR and the global HEOR community to support initiatives that advance and strengthen HEOR, in alignment with ISPOR’s Strategic Plan 2030. This includes cutting edge research, education and training, and enhancing health outcomes research through evidence-based practices throughout the wider healthcare industry.

“We are very excited to launch the new Corporate Partner Program, welcome Genesis Research Group, and invite them and other organizations to contribute to ISPOR’s vision of a world where healthcare is accessible, effective, efficient, and affordable for all,” commented Rob Abbott, CEO of ISPOR. “Organizations who become ISPOR Corporate Partners will take an active role in the Society’s mission to improve healthcare decisions and achieving this vision, while elevating their presence with key stakeholders.”

“The importance of leveraging HEOR to inform healthcare decision-making has never been greater. By supporting ISPOR and becoming an inaugural member of its Corporate Partnership Program, we are reaffirming our dedication to leveraging real-world evidence, market access, and HEOR transparently and ethically to ensure that healthcare decisions are guided by high-quality evidence,” said David W. Miller, CEO of Genesis Research Group. “We are delighted to join other industry leaders in taking an active role in shaping the future of HEOR.”

MEET GENESIS RESEARCH GROUP AT ISPOR 2025 IN MONTREAL!

Contact solutions@genesisrg.com.

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Group launches Keystone IEGP platform at ISPOR Europe 2026

Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will…

On GLOBE Final Rule

The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally….

Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.

On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…

Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview

At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…